ReviewCancer management and research2020
Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies.
Review in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Nivolumab rechallenge after pituitary apoplexy associated with nivolumab plus ipilimumab in a patient with pituitary adenoma and rectal melanoma: a case report and literature review.Journal of pharmaceutical health care and sciences · 2026Article
- Effects of immune checkpoint inhibitors on perioperative endocrine abnormalities and intraoperative hemodynamics in patients undergoing radical gastrectomy: a retrospective propensity score-matched cohort study.Journal of anesthesia · 2026Article
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.Frontiers in oncology · 2026Article
- Clinical characteristics, management, and prognosis of ipilimumab-induced hypophysitis: a retrospective analysis of 76 cases.Frontiers in endocrinology · 2026Article
- Article
- Review
- Mimickers of pituitary tumors.Neuro-oncology advances · 2025Article
- Immune checkpoint inhibitor induced hypophysitis: a specific disease of corticotrophs?Endocrine connections · 2024Article
- Immune checkpoint inhibitor-associated new-onset hypophysitis: a retrospective analysis using the FAERS.Endocrine · 2024Article
- Secondary adrenocortical insufficiency after treatment with retifanlimab: a case report.Frontiers in immunology · 2024Article
- Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.Clinical and experimental medicine · 2023Review
- Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review.Current oncology (Toronto, Ont.) · 2023Review
- Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.International journal of clinical oncology · 2023Article
- Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic.Global challenges (Hoboken, NJ) · 2023Review
- Endocrine side effects of immune checkpoint inhibitors.Frontiers in endocrinology · 2023Review
- Early Detection of Immune-Mediated Hypophysitis With Use of Checkpoint Inhibitor Immunotherapy.Cureus · 2022Article
- Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study.Annals of translational medicine · 2022Article
- Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.PloS one · 2022Article
- Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease.The Journal of clinical endocrinology and metabolism · 2022Review
- Immunotherapy-Induced Anterior Hypophysitis.Cureus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past years, progress has been made in cancer immunotherapy following the development of immune checkpoint inhibitors (ICI) that have been proved effective in the management of many malignancies. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4), has been approved for the treatment of advanced melanoma but has been associated with the development of several endocrine immune-related adverse events (irAEs). Hypophysitis is the most common endocrine irAE related to ipilimumab with a reported incidence ranging from 1.8% to 17%. The mechanism underlying ipilimumab-induced hypophysitis implicates immune, inflammatory and genetic factors, but there are still some points that are not well understood and remain to be elucidated. The diagnosis is based mainly on clinical, biochemical and imaging data. The majority of patients display multiple hormone deficiencies that may recover or persist for a prolonged period of time with corticotroph deficiency usually being permanent. Immune-related hypopituitarism is treated with replacement of deficient hormones while in severe forms of hypophysitis treatment with high-dose glucocorticoids may be required. Proper evaluation and registration of patients in clinical trials and further investigation are needed to precisely clarify the pathophysiology of the ICI-related hypophysitis, define predictive factors and ameliorate the management and outcome of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.